CliffBio
small molecule

RISPERIDONE

RISPERIDONE

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameRISPERIDONE
Active ingredientRISPERIDONE
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2012
Marketing statusRX

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RISPERIDONE patent cliff — loss of exclusivity — | CliffBio